RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+4.51%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.46B
AUM Growth
+$6.46B
(-4.7%)
Cap. Flow
+$257M
Cap. Flow
% of AUM
3.98%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
76
New
7
Increased
23
Reduced
12
Closed
8
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$426M |
| 2 |
Insmed
INSM
|
$119M |
| 3 |
Dyne Therapeutics
DYN
|
$116M |
| 4 |
Intuitive Surgical
ISRG
|
$46M |
| 5 |
Glaukos
GKOS
|
$38.8M |
Top Sells
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$157M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$149M |
| 3 |
Stryker
SYK
|
$115M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$94M |
| 5 |
Thermo Fisher Scientific
TMO
|
$64.2M |
Sector Composition
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $537M | 8.31% | 1,915,862 +1,518,815 | +383% | +$426M |
|
2
Rocket Pharmaceuticals
RCKT
$354M
| $381M | 5.9% | 17,687,772 | – | – |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $373M | 5.78% | 4,634,331 +141,652 | +3% | +$11.4M |
|
4
Avidity Biosciences
RNA
$5.99B
| $360M | 5.57% | 8,806,838 +836,569 | +10% | +$34.2M |
|
5
argenx
ARGX
$43.6B
| $281M | 4.36% | 654,430 -12,765 | -2% | -$5.49M |
|
6
Natera
NTRA
$23.1B
| $281M | 4.35% | 2,593,323 | – | – |
|
7
Merus
MRUS
$4.98B
| $247M | 3.82% | 4,169,393 +60,000 | +1% | +$3.55M |
|
|
8
Insmed
INSM
$28.8B
| $244M | 3.78% | 3,640,108 +1,775,000 | +95% | +$119M |
|
9
PTC Therapeutics
PTCT
$3.92B
| $226M | 3.5% | 7,393,127 -30,843 | -0.4% | -$943K |
|
|
10
Dyne Therapeutics
DYN
$1.92B
| $225M | 3.49% | 6,387,138 +3,295,551 | +107% | +$116M |
|
11
Acadia Pharmaceuticals
ACAD
$4.38B
| $223M | 3.45% | 13,707,506 -121,809 | -0.9% | -$1.98M |
|
12
Bruker
BRKR
$5.16B
| $220M | 3.4% | 3,444,095 +100,000 | +3% | +$6.38M |
|
13
Masimo
MASI
$7.59B
| $184M | 2.85% | 1,462,400 | – | – |
|
14
Protagonist Therapeutics
PTGX
$3.67B
| $183M | 2.84% | 5,286,404 -29,110 | -0.5% | -$1.01M |
|
15
Alkermes
ALKS
$4.78B
| $170M | 2.63% | 7,056,988 +1,002,708 | +17% | +$24.2M |
|
16
Immunocore
IMCR
$1.62B
| $165M | 2.56% | 4,869,798 -1,149,843 | -19% | -$39M |
|
17
Cytokinetics
CYTK
$4.23B
| $147M | 2.28% | 2,721,158 +196,078 | +8% | +$10.6M |
|
|
18
Ultragenyx Pharmaceutical
RARE
$2.89B
| $134M | 2.07% | 3,259,927 -3,827,188 | -54% | -$157M |
|
19
Penumbra
PEN
$10.6B
| $134M | 2.07% | 742,105 +66,217 | +10% | +$11.9M |
|
20
Akero Therapeutics
AKRO
$3.74B
| $127M | 1.97% | 5,431,985 | – | – |
|
21
Establishment Labs
ESTA
$1.2B
| $122M | 1.88% | 2,675,703 | – | – |
|
22
Immatics
IMTX
$619M
| $116M | 1.8% | 10,000,000 | – | – |
|
23
RadNet
RDNT
$5.52B
| $109M | 1.69% | 1,856,010 +155,460 | +9% | +$9.16M |
|
24
Apogee Therapeutics
APGE
$2.17B
| $107M | 1.65% | 2,712,096 +244,505 | +10% | +$9.62M |
|
25
Tarsus Pharmaceuticals
TARS
$2.47B
| $92.8M | 1.44% | 3,412,486 +140,145 | +4% | +$3.81M |
|